Why Is BEAM THERAPEUTICS IN (BEAM) Stock Down Today?
By the Top Tier Newswire AI Desk · September 9, 2026 at 12:25 AM ET · reviewed against 7 wire stories
BEAM THERAPEUTICS IN (BEAM) is down -9.54% in the latest session. Our newswire has captured 7 stories on BEAM across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 49/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
BEAM stock fell 9.54% to $26.83 on September 8, driven by updated clinical data from its Phase 1/2 trial for BEAM-302, a gene-editing therapy for alpha-1 antitrypsin deficiency. The data, presented at the European Respiratory Society Congress 2026, failed to meet expectations, prompting the company to adjust its regulatory strategy. Beam Therapeutics announced it will pursue an accelerated approval pathway and add 50 more patients to its trial.
What Happened
Beam Therapeutics released updated results for BEAM-302, its one-time gene-editing treatment for AATD, showing AAT protein production under normal physiological control. However, the data did not meet the expectations of investors or analysts, leading to a sharp decline in the stock. The company announced it will seek accelerated approval from the FDA and enroll additional patients to support a future biologics license application. This shift in strategy signals a longer path to commercialization than previously anticipated.
The stock has been volatile in recent weeks, with insiders including CEO John M. Evans and Chief Medical Officer Simon Amy selling shares. The CMO sold on both June 30 and July 27, while the CEO sold on June 29. The most recent insider sale was reported on July 29. Over the past 8 sessions, the stock has declined 11.7% from $30.48 to $26.90.
What The Data Shows
The stock has a market cap of $3.0B and is currently unprofitable, with a trailing twelve-month EPS of -0.84 and a net margin of -55.4%. Revenue grew by 158.9% in the TTM period. The stock traded within a 52-week range of $17.74 to $38.26. On September 8, it printed two fresh 52-week lows and one fresh 52-week high. Volume was unusually high, though specific figures are not provided. The stock’s beta of 2.23 indicates strong volatility relative to the broader market.
What To Watch
Beam Therapeutics is scheduled to present further updates on BEAM-302 in the coming weeks. Investors will also monitor the company’s progress toward its accelerated approval pathway and any changes in coverage from analysts.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BEAM · Sep 9 session (5-min) · -5.48% vs prior close · updated 8:58 PM ETAI sentiment, last 36h · averaged over 7 stories · 49/100 neutral
The headlines behind the move
Story flow · 7 stories on the wire, last 36h · hover or tap a dot for the headline
4d agoMorningstarBEARISH 34General
Shares of Beam Therapeutics Retreat After Updated Trial Data Disappoints
Based on the feedback from the Food and Drug Administration, Beam plans to pursue an accelerated approval pathway for the treatment. Beam plans to enroll 50 additional patients to support a future biologics license application, the company said.
4d agoBusiness InsiderBEARISH 38Earnings
Beam drops after updating Phase 1/2 trial data for gene-editing drug
Beam Therapeutics (BEAM) stock slips on updated data from a Phase 1/2 trial for BEAM-302, its gene-editing drug for alpha-1 antitrypsin deficiency. Read more here.
4d agoSeeking AlphaBULLISH 59Product/PR
Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript
Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency September 8, 2026 7:00 AM EDTCompany...
4d agoThe FlyBEARISH 38General
Beam Therapeutics falls -12.4%
4d agoThe FlyBEARISH 38General
Beam Therapeutics falls -12.7%
5d agoThe FlyBULLISH 67Product/PR
Beam Therapeutics’ BEAM-302 shows efficacy in Phase 1/2 AATD trial
5d agoBusiness InsiderBULLISH 67Product/PR
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →